questionText: To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 9 July 2025 to Question 64681 on Prostate Cancer: Hormone Treatments, for what reason recurrent headroom in revenue budgets is considered a barrier to implementing the abiraterone acetate plus prednisone/prednisolone treatment.
answerText: Reimbursement of abiraterone across all indications is managed at a national level by NHS England who must ensure the affordability of introducing any new routine commissioning policies, alongside maintaining existing services for patients and meeting the...
heading: Prostate Cancer: Hormone Treatments